Corbus Pharmaceuticals Holdings, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Corbus Pharmaceuticals Holdings, Inc. on November 27, 2017. The Company is an emerging growth company incorporated in Delaware. The report details the closing of a specific equity transaction related to a previously announced underwriting agreement.
Key Financial Metrics
- Transaction Type: Exercise of underwriters' 30-day option to purchase additional shares.
- Shares Issued: 697,500 newly issued shares of common stock (Option Shares).
- Price Per Share: $7.00.
- Net Proceeds: Approximately $4.6 million (after deducting underwriting discounts, commissions, and estimated offering expenses).
- Underwriter: Cantor Fitzgerald & Co. (as representative).
Material Changes
The primary material event reported is the full exercise of the underwriters' option on November 27, 2017. This transaction increased the Company's share count and provided additional capital. The terms of the underlying Underwriting Agreement were previously disclosed in an 8-K filed on October 24, 2017.
Outlook, Risks, and Management Commentary
The filing references a press release issued on November 27, 2017, regarding the closing of the sale. The document does not contain specific forward-looking guidance, risk factors, or management commentary beyond the factual reporting of the transaction closing and the incorporation of the press release by reference.
Key Facts for Investor Verification
- Verify the total number of shares outstanding post-transaction to assess dilution impact.
- Confirm the specific use of the approximately $4.6 million in net proceeds as outlined in the referenced press release.
- Review the October 24, 2017 Form 8-K for the full terms of the Underwriting Agreement.
- Note that the Company has elected to use the extended transition period for complying with new or revised financial accounting standards as an emerging growth company.